^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
For the highly selected patients with ER positive/HER2-positive ABC, for whom ET plus anti-HER2 therapy was chosen as first-line therapy, dual anti-HER2 blockade (with either pertuzumab plus trastuzumab or lapatinib plus trastuzumab) can be used since it provides a benefit in PFS.
